Plasminogen activator, fibronectin, lymphotoxin sensitivity, and natural skin reactivity relationships to guinea pig cell tumorigenicity. 1982

R P McCabe, and C H Evans

The quantitative expression of five properties of chemical carcinogen-induced, neoplastically transformed NIH strain 2 guinea pig fibroblasts was compared in cells possessing thousandfold differences in tumorigenicity. Plasminogen activator synthesis, sensitivity to lymphotoxin inhibition of cell proliferation, and the ability to induce a natural delayed tuberculin-type skin reaction in nonimmune syngeneic guinea pigs correlated directly with the number of cells required to produce a tumor. The most tumorigenic cells (10(2)-cell threshold dose) produced the most plasminogen activator, were most sensitive to lymphotoxin, and produced the greatest skin reactivity. Cells with a threshold tumor dose of 10(5)-10(7) cells exhibited the lowest expression of these properties. Fibronectin incorporation into an extracellular matrix was diminished in tumorigenic cells, as was anchorage-dependent growth; but neither diminished fibronectin incorporation nor the decreased anchorage requirement correlated quantitatively with the number of cells required to produce a tumor. The present investigation indicates that plasminogen activator synthesis, sensitivity to lymphotoxin, and the capacity of tumorigenic cells to induce natural delayed-type skin reactivity are among the factors that influence initial tumor growth. Plasminogen activator, an extracellular protease, may aid in the growth and spread of tumor cells in vivo by interfering with host fibrin deposition and by inactivating other host proteins such as lymphotoxin.

UI MeSH Term Description Entries
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012882 Skin Tests Epicutaneous or intradermal application of a sensitizer for demonstration of either delayed or immediate hypersensitivity. Used in diagnosis of hypersensitivity or as a test for cellular immunity. Skin Test,Test, Skin,Tests, Skin

Related Publications

R P McCabe, and C H Evans
January 1979, Immunology,
R P McCabe, and C H Evans
October 1985, The Journal of biological chemistry,
R P McCabe, and C H Evans
March 1978, Journal of immunology (Baltimore, Md. : 1950),
R P McCabe, and C H Evans
April 1973, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
R P McCabe, and C H Evans
December 1979, Immunopharmacology,
R P McCabe, and C H Evans
January 1974, Journal of immunology (Baltimore, Md. : 1950),
R P McCabe, and C H Evans
August 1976, The Japanese journal of experimental medicine,
Copied contents to your clipboard!